Background: Cannabis legalization is expanding, but there are no established methods for detecting cannabis impairment.
Aim: Characterize the acute impairing effects of oral and vaporized cannabis using various performance tests.
Methods: Participants ( = 20, 10 men/10 women) who were infrequent cannabis users ingested cannabis brownies (0, 10, and 25 mg Δ-9-tetrahydrocannabinol, THC) and inhaled vaporized cannabis (0, 5, and 20 mg THC) in six double-blind outpatient sessions. Cognitive/psychomotor impairment was assessed with a battery of computerized tasks sensitive to cannabis effects, a novel test (the DRiving Under the Influence of Drugs, DRUID), and field sobriety tests. Blood THC concentrations and subjective drug effects were evaluated.
Results: Low oral/vaporized doses did not impair cognitive/psychomotor performance relative to placebo but produced positive subjective effects. High oral/vaporized doses impaired cognitive/psychomotor performance and increased positive and negative subjective effects. The DRUID was the most sensitive test to cannabis impairment, as it detected significant differences between placebo and active doses within both routes of administration. Women displayed more impairment on the DRUID than men at the high vaporized dose only. Field sobriety tests showed little sensitivity to cannabis-induced impairment. Blood THC concentrations were far lower after cannabis ingestion versus inhalation. After inhalation, blood THC concentrations typically returned to baseline well before pharmacodynamic effects subsided.
Conclusions: Standard approaches for identifying impairment due to cannabis exposure (i.e. blood THC and field sobriety tests) have severe limitations. There is a need to identify novel biomarkers of cannabis exposure and/or behavioral tests like the DRUID that can reliably and accurately detect cannabis impairment at the roadside and in the workplace.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361180 | PMC |
| http://dx.doi.org/10.1177/02698811211021583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Cannabis is increasingly used and debates about the legalisation of the recreational use of cannabis are ongoing. In this prospective, placebo-controlled study in healthy volunteers not regularly consuming cannabis, subjective psychotropic and somatic effects after a single dose of intravenous THC were assessed and quantified over 48 h.
Methods: Twenty-five healthy volunteers received a single IV bolus of THC and 6 received normal saline.
Intraperitoneal delivery of cannabidiol (CBD) and Δ-tetrahydocannabinol (THC) promotes papillomavirus infections in athymic nude mice.
Tumour Virus Res
December 2024
The Jake Gittlen Laboratories for Cancer Research, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA; Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA. Electronic address:
We used our mouse papillomavirus (MmuPV1) model to test the hypothesis that two primary psychoactive ingredients of marijuana, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), promote papillomavirus persistence in the oral mucosa of infected mice. We conducted intraperitoneal (ip) injections of a moderate dose (3 mg/kg) of either CBD and/or THC in both male and female athymic nude mice and followed the mice up to 20 weeks post-infection. These doses are comparable to what is estimated for human conventional cannabis consumption.
View Article and Find Full Text PDFNear-infrared diffuse optical characterization of human thyroid using ultrasound-guided hybrid time-domain and diffuse correlation spectroscopies.
Biomed Opt Express
December 2024
ICFO - Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, 08860 Castelldefels (Barcelona), Spain.
Thyroid vascularization and hemodynamics become altered in thyroid pathologies and could thus inform diagnostics, therapy planning, and follow-up. However, the current non-invasive monitoring methods available in clinics lack the necessary sensitivity and/or are impractical for large-scale deployment. As a step towards proposing a new modality, we applied the first platform, to our knowledge, designed to do simultaneous measurements of neck anatomy and thyroid microvascular hemodynamics and metabolism in a single probe placement, integrating state-of-the-art near-infrared spectroscopy techniques and clinical ultrasound.
View Article and Find Full Text PDFQuantification of ∆9-tetrahydrocannabinol (THC), 11-OH-THC, THC-COOH, hexahydrocannabinol and cannabidiol in human plasma and blood by liquid chromatography-tandem mass spectrometry.
J Anal Toxicol
December 2024
Institute of Legal Medicine, Medical University of Innsbruck, Muellerstrasse 44, 6020 Innsbruck, Austria.
Ongoing legalization of cannabis for recreational use contributes to increasing numbers not only of incidents of driving under the influence, but within all forensic fields. In addition, newly emerging cannabinoids such as hexahydrocannabinol (HHC) and the increasing use of cannabidiol (CBD) products have to be addressed. The aims of this study were first to extend laboratory analysis capacity for the "established" cannabinoid ∆9-tetrahydrocannabinol (THC) and its metabolites 11-OH-THC and THC-COOH in human plasma/blood, and second to develop analytical procedures concerning HHC and CBD.
View Article and Find Full Text PDFA Preliminary Pharmacokinetic Comparison of Δ-9 Tetrahydrocannabinol and Cannabidiol Extract Versus Oromucosal Spray in Healthy Men and Women.
Cannabis Cannabinoid Res
December 2024
Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, New York, USA.
Few studies have directly compared the bioavailability of different cannabinoid formulations. Our goal was to assess the pharmacokinetic parameters and relative bioavailability of two Δ9-tetrahydrocannabinol:cannabidiol (THC:CBD) formulations: orally administered THC:CBD extract and oromucosally administered nabiximols. This pilot crossover study counterbalanced (1) 1 mL of orally administered THC:CBD extract (10 mg/mL each of THC and CBD in grapeseed oil) and (2) oromucosally administered nabiximols (four sprays of 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!